JP2019527053A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2019527053A5 JP2019527053A5 JP2019500261A JP2019500261A JP2019527053A5 JP 2019527053 A5 JP2019527053 A5 JP 2019527053A5 JP 2019500261 A JP2019500261 A JP 2019500261A JP 2019500261 A JP2019500261 A JP 2019500261A JP 2019527053 A5 JP2019527053 A5 JP 2019527053A5
- Authority
- JP
- Japan
- Prior art keywords
- polypeptide
- item
- sfgfr3
- growth factor
- fibroblast growth
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2022046573A JP7348980B2 (ja) | 2016-07-07 | 2022-03-23 | 可溶性線維芽細胞成長因子受容体３（ｓＦＧＦＲ３）ポリペプチドおよびその使用 |
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662359607P | 2016-07-07 | 2016-07-07 | |
| US62/359,607 | 2016-07-07 | ||
| US201762467478P | 2017-03-06 | 2017-03-06 | |
| US62/467,478 | 2017-03-06 | ||
| PCT/EP2017/067119 WO2018007597A1 (en) | 2016-07-07 | 2017-07-07 | Soluble fibroblast growth factor receptor 3 (sfgfr3) polypeptides and uses thereof |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022046573A Division JP7348980B2 (ja) | 2016-07-07 | 2022-03-23 | 可溶性線維芽細胞成長因子受容体３（ｓＦＧＦＲ３）ポリペプチドおよびその使用 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2019527053A JP2019527053A (ja) | 2019-09-26 |
| JP2019527053A5 true JP2019527053A5 (enExample) | 2020-08-20 |
| JP7046903B2 JP7046903B2 (ja) | 2022-04-04 |
Family
ID=59381265
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019500261A Expired - Fee Related JP7046903B2 (ja) | 2016-07-07 | 2017-07-07 | 可溶性線維芽細胞成長因子受容体３（ｓＦＧＦＲ３）ポリペプチドおよびその使用 |
| JP2022046573A Active JP7348980B2 (ja) | 2016-07-07 | 2022-03-23 | 可溶性線維芽細胞成長因子受容体３（ｓＦＧＦＲ３）ポリペプチドおよびその使用 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022046573A Active JP7348980B2 (ja) | 2016-07-07 | 2022-03-23 | 可溶性線維芽細胞成長因子受容体３（ｓＦＧＦＲ３）ポリペプチドおよびその使用 |
Country Status (20)
| Country | Link |
|---|---|
| US (3) | US10294289B2 (enExample) |
| EP (2) | EP4122955A1 (enExample) |
| JP (2) | JP7046903B2 (enExample) |
| KR (2) | KR102432192B1 (enExample) |
| CN (1) | CN109715658B (enExample) |
| AU (2) | AU2017294551B2 (enExample) |
| BR (1) | BR112019000257A2 (enExample) |
| CA (1) | CA3029877C (enExample) |
| DK (1) | DK3481859T3 (enExample) |
| ES (1) | ES2912559T3 (enExample) |
| HU (1) | HUE058734T2 (enExample) |
| IL (1) | IL264030A (enExample) |
| MX (1) | MX2018016257A (enExample) |
| PL (1) | PL3481859T3 (enExample) |
| PT (1) | PT3481859T (enExample) |
| RU (1) | RU2751483C2 (enExample) |
| SG (1) | SG11201900074WA (enExample) |
| SI (1) | SI3481859T1 (enExample) |
| WO (1) | WO2018007597A1 (enExample) |
| ZA (1) | ZA201900507B (enExample) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EA201591324A1 (ru) | 2013-01-16 | 2016-01-29 | Инсерм (Энститю Насьональ Де Ля Сантэ Э Де Ля Решерш Медикаль) | Полипептид растворимого рецептора 3 фактора роста фибробластов (fgr3) для применения с целью предотвращения или лечения нарушений, связанных с замедлением роста скелета |
| RU2751483C2 (ru) | 2016-07-07 | 2021-07-14 | Пфайзер Инк. | Полипептиды, являющиеся растворимыми рецепторами 3 фактора роста фибробластов (sfgfr3), и пути их применения |
| BR112020005459A2 (pt) * | 2017-09-20 | 2020-09-29 | Pfizer Inc. | tratamento de deposição de gordura visceral anormal usando polipeptídeos de receptor 3 de fator de crescimento de fibroblasto solúvel (sfgfr3) |
| US12390510B2 (en) | 2019-05-29 | 2025-08-19 | Massachusetts Eye And Ear Infirmary | Methods of treating sensorineural hearing loss using fibroblast growth factor 2 (FGF2) |
| US11625937B2 (en) * | 2020-04-06 | 2023-04-11 | Toyota Motor Engineering & Manufacturing North America, Inc. | Methods and systems for monitoring human body weight with vehicle sensors and big data AI analytics |
| WO2022106976A1 (en) | 2020-11-18 | 2022-05-27 | Pfizer Inc. | Stable pharmaceutical formulations of soluble fgfr3 decoys |
| JP2022184798A (ja) | 2021-06-01 | 2022-12-13 | ファイザー・インク | ｓＦＧＦＲ３ポリペプチドを生産するための細胞培養方法 |
| WO2024104922A1 (en) | 2022-11-14 | 2024-05-23 | Ascendis Pharma Growth Disorders A/S | Method of improving skeletal muscle function |
| WO2024194300A1 (en) | 2023-03-20 | 2024-09-26 | Ascendis Pharma Growth Disorders A/S | Method of treatment of a thoracolumbar deformity in a human subject with achondroplasia |
| CN116284327A (zh) * | 2023-03-28 | 2023-06-23 | 中国药科大学 | 一种靶向肿瘤的成纤维细胞生长因子19的重组蛋白及其应用 |
Family Cites Families (36)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB8308236D0 (en) | 1983-03-25 | 1983-05-05 | Celltech Ltd | Dna vectors |
| EP1342476A3 (en) | 1995-06-12 | 2003-09-17 | Yeda Research And Development Co. Ltd. | FGFR3 as a marker for mesenchymal skeletal progenitor cells and use of cytotoxic conjugates comprising an FGFR3 binding agent for the treatment of cartilagineous bony tumours |
| US7067144B2 (en) | 1998-10-20 | 2006-06-27 | Omeros Corporation | Compositions and methods for systemic inhibition of cartilage degradation |
| WO2002050246A2 (en) | 2000-12-18 | 2002-06-27 | Gene Logic, Inc. | Treatment of bone disorders by modulation of fgfr3 |
| IL142118A0 (en) | 2001-03-20 | 2002-03-10 | Prochon Biotech Ltd | Method and composition for treatment of skeletal dysplasias |
| CA2450793A1 (en) | 2001-06-20 | 2002-12-27 | Prochon Biotech Ltd. | Antibodies that block receptor protein tyrosine kinase activation, methods of screening for and uses thereof |
| BRPI0203172B8 (pt) | 2001-09-28 | 2021-05-25 | Nakao Kazuwa | composição farmacêutica para acondroplasia |
| JP2003104908A (ja) | 2001-09-28 | 2003-04-09 | Ichikazu Nakao | 軟骨無形成症治療剤 |
| IL156495A0 (en) | 2003-06-17 | 2004-01-04 | Prochon Biotech Ltd | Use of fgfr3 antagonists for treating t cell mediated diseases |
| DK1718756T3 (da) | 2004-02-24 | 2012-02-27 | Allergan Inc | Botulinumtoksinscreeningassays |
| EP2083081A1 (en) | 2005-07-22 | 2009-07-29 | Five Prime Therapeutics, Inc. | Compositions and methods of treating disease with FGFR fusion proteins |
| US8101721B2 (en) | 2006-06-15 | 2012-01-24 | Fibron Ltd. | Antibodies blocking fibroblast growth factor receptor activation and methods of use thereof |
| US8962556B2 (en) | 2006-09-28 | 2015-02-24 | Prochon Biotech Ltd. | FGF-2 variants having N-terminal deletions and increased receptor selectivity and uses thereof |
| WO2008133873A2 (en) | 2007-04-25 | 2008-11-06 | Aveo Pharmaceuticals, Inc. | Fgf-binding fusion proteins |
| US8426396B2 (en) | 2008-01-08 | 2013-04-23 | Shriners Hospitals For Children | Treatment for achondroplasia |
| US8187601B2 (en) | 2008-07-01 | 2012-05-29 | Aveo Pharmaceuticals, Inc. | Fibroblast growth factor receptor 3 (FGFR3) binding proteins |
| BRPI0916904A2 (pt) | 2008-08-04 | 2016-10-11 | Fiveprime Therapeutics Inc | polipeptídeos, moléculares de fusão ecd fgfr4, composições farmacêuticas, polinucleotídio e métodos de tratamento de desordem angiogênica, câncer em paciente e degeneração macular em paciente e respectivos usos |
| TWI381848B (zh) | 2008-10-20 | 2013-01-11 | Imclone Llc | 抗纖維母細胞生長因子受體-3 (fgfr-3) 抗體及包含其之醫藥組合物 |
| EP3702371B1 (en) | 2009-03-25 | 2022-11-02 | Genentech, Inc. | Anti-fgfr3 antibodies and methods using same |
| WO2011034940A1 (en) | 2009-09-15 | 2011-03-24 | Five Prime Therapeutics, Inc. | Hair growth methods using fgfr4 extracellular domains |
| LT2498799T (lt) | 2009-11-13 | 2016-11-10 | Five Prime Therapeutics, Inc. | Fgfr1 ekstraląstelinio domeno baltymų panaudojimas gydymui vėžio su nuo ligando priklausančiomis, aktyvuojančiomis fgfr2 mutacijomis |
| WO2011084711A2 (en) * | 2009-12-17 | 2011-07-14 | Five Prime Therapeutics, Inc. | Hair growth methods using fgfr3 extracellular domains |
| EP2523679A4 (en) | 2010-01-14 | 2013-07-24 | Univ Yale Inc | RECEPTORT SYROSINE KINASE (RTK) INHIBITOR AND ITS USE METHOD |
| US8481038B2 (en) | 2010-11-15 | 2013-07-09 | Five Prime Therapeutics, Inc. | Treatment of cancer with elevated dosages of soluble FGFR1 fusion proteins |
| US9266939B2 (en) | 2010-12-27 | 2016-02-23 | Alexion Pharmaceuticals, Inc. | Compositions comprising natriuretic peptides and methods of use thereof |
| CN102219860B (zh) | 2011-05-20 | 2012-09-12 | 烟台荣昌生物工程有限公司 | FGFR-Fc融合蛋白及其用途 |
| KR101828828B1 (ko) | 2011-10-24 | 2018-03-29 | 할로자임, 아이엔씨 | 항-히알루로난 제제 치료를 위한 동반 진단 및 이의 사용 방법 |
| FR2984325A1 (fr) | 2011-12-14 | 2013-06-21 | Sanofi Sa | Derives de pyrazolopyridine, leur procede de preparation et leur application en therapeutique |
| AU2013295805B2 (en) | 2012-07-24 | 2019-05-02 | The Trustees Of Columbia University In The City Of New York | Fusion proteins and methods thereof |
| WO2014018841A1 (en) | 2012-07-27 | 2014-01-30 | Genentech, Inc. | Methods of treating fgfr3 related conditions |
| HK1214831A1 (zh) | 2012-11-05 | 2016-08-05 | Foundation Medicine, Inc. | 新型融合分子及其应用 |
| EA201591324A1 (ru) | 2013-01-16 | 2016-01-29 | Инсерм (Энститю Насьональ Де Ля Сантэ Э Де Ля Решерш Медикаль) | Полипептид растворимого рецептора 3 фактора роста фибробластов (fgr3) для применения с целью предотвращения или лечения нарушений, связанных с замедлением роста скелета |
| AU2015209131B2 (en) | 2014-01-24 | 2020-06-25 | Ngm Biopharmaceuticals, Inc. | Binding proteins and methods of use thereof |
| SI3242888T1 (sl) | 2015-01-07 | 2021-07-30 | Pfizer Inc. | Topne vabe FGFR3 za zdravljenje motenj rasti skeleta |
| RU2751483C2 (ru) | 2016-07-07 | 2021-07-14 | Пфайзер Инк. | Полипептиды, являющиеся растворимыми рецепторами 3 фактора роста фибробластов (sfgfr3), и пути их применения |
| BR112020005459A2 (pt) | 2017-09-20 | 2020-09-29 | Pfizer Inc. | tratamento de deposição de gordura visceral anormal usando polipeptídeos de receptor 3 de fator de crescimento de fibroblasto solúvel (sfgfr3) |
-
2017
- 2017-07-07 RU RU2019100381A patent/RU2751483C2/ru active
- 2017-07-07 AU AU2017294551A patent/AU2017294551B2/en not_active Ceased
- 2017-07-07 SG SG11201900074WA patent/SG11201900074WA/en unknown
- 2017-07-07 ES ES17742195T patent/ES2912559T3/es active Active
- 2017-07-07 KR KR1020197002602A patent/KR102432192B1/ko active Active
- 2017-07-07 KR KR1020227027503A patent/KR20220122762A/ko not_active Ceased
- 2017-07-07 WO PCT/EP2017/067119 patent/WO2018007597A1/en not_active Ceased
- 2017-07-07 PT PT177421955T patent/PT3481859T/pt unknown
- 2017-07-07 BR BR112019000257A patent/BR112019000257A2/pt not_active IP Right Cessation
- 2017-07-07 CA CA3029877A patent/CA3029877C/en active Active
- 2017-07-07 SI SI201731158T patent/SI3481859T1/sl unknown
- 2017-07-07 MX MX2018016257A patent/MX2018016257A/es unknown
- 2017-07-07 PL PL17742195T patent/PL3481859T3/pl unknown
- 2017-07-07 JP JP2019500261A patent/JP7046903B2/ja not_active Expired - Fee Related
- 2017-07-07 EP EP22167483.1A patent/EP4122955A1/en not_active Withdrawn
- 2017-07-07 DK DK17742195.5T patent/DK3481859T3/da active
- 2017-07-07 HU HUE17742195A patent/HUE058734T2/hu unknown
- 2017-07-07 EP EP17742195.5A patent/EP3481859B1/en active Active
- 2017-07-07 CN CN201780049433.8A patent/CN109715658B/zh not_active Expired - Fee Related
-
2018
- 2018-04-02 US US15/943,436 patent/US10294289B2/en active Active
- 2018-12-30 IL IL264030A patent/IL264030A/en unknown
-
2019
- 2019-01-24 ZA ZA2019/00507A patent/ZA201900507B/en unknown
- 2019-05-20 US US16/417,174 patent/US11021528B2/en not_active Expired - Fee Related
-
2021
- 2021-04-20 US US17/234,841 patent/US11697678B2/en active Active
-
2022
- 2022-03-23 JP JP2022046573A patent/JP7348980B2/ja active Active
- 2022-05-02 AU AU2022202906A patent/AU2022202906A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2019527053A5 (enExample) | ||
| CN102718858B (zh) | 胰高血糖素样肽-1类似物单体、二聚体及其制备方法与应用 | |
| RU2019100381A (ru) | Полипептиды, являющиеся растворимыми рецепторами 3 фактора роста фибробластов (sfgfr3), и пути их применения | |
| ES2389697T3 (es) | Variantes de desintegrina y usos farmacéuticos de los mismos | |
| JP2017529059A5 (enExample) | ||
| CN102643339B (zh) | 一种glp-1类似物、制备方法及其应用 | |
| JP2014534265A5 (enExample) | ||
| JP7672122B2 (ja) | 生物活性複合体の調製 | |
| JP7702445B2 (ja) | 免疫調節融合タンパク質 | |
| JP2016518351A5 (enExample) | ||
| CN112521514A (zh) | 一种蛋白复合物及其制备方法和应用 | |
| JP2022523972A (ja) | 増殖分化因子１５併用療法 | |
| AU2015356997A1 (en) | CD44v6-derived cyclic peptides for treating cancers and angiogenesis related diseases | |
| US20200062811A1 (en) | Yap protein inhibiting polypeptide and application thereof | |
| CN103732240B (zh) | G-csf二聚体在制备治疗神经退行性疾病药物中的应用 | |
| CN101208106B (zh) | 癌症治疗剂 | |
| HUP0104126A2 (hu) | Gyógyszer a csontmetabolizmus hibáira | |
| CA3133830A1 (en) | Fms-like tyrosine kinase 3 ligand (flt3l)-based chimeric proteins | |
| KR102745928B1 (ko) | 혈액뇌장벽을 통과 가능한 폴리펩티드 | |
| CN113355308A (zh) | 用于中和冠状病毒的人工多肽、制备方法及药物组合物 | |
| JPH07503705A (ja) | 医薬的リジン含有ポリペプチド組成物およびその使用法 | |
| JP2008509888A (ja) | 上皮成長因子受容体アンタゴニストおよび使用方法 | |
| JP4560612B2 (ja) | デコリン由来ペプチド | |
| JPH08333274A (ja) | 悪性腫瘍治療用キット | |
| JP2001523727A (ja) | 造血幹細胞を可動化する方法 |